Mayank Mamtani
Stock Analyst at B. Riley Securities
(4.30)
# 311
Out of 4,829 analysts
126
Total ratings
38.39%
Success rate
30.42%
Average return
Main Sectors:
Stocks Rated by Mayank Mamtani
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDGL Madrigal Pharmaceuticals | Reiterates: Buy | $422 → $460 | $299.69 | +53.49% | 12 | May 2, 2025 | |
| HROW Harrow | Maintains: Buy | $69 → $65 | $24.40 | +166.39% | 2 | Apr 1, 2025 | |
| VXRT Vaxart | Maintains: Buy | $2.5 → $2 | $0.42 | +376.64% | 6 | Mar 27, 2025 | |
| TRVI Trevi Therapeutics | Reiterates: Buy | $11 → $20 | $6.60 | +203.03% | 3 | Mar 19, 2025 | |
| LCTX Lineage Cell Therapeutics | Maintains: Buy | $4 → $3 | $0.44 | +581.82% | 2 | Mar 14, 2025 | |
| DNLI Denali Therapeutics | Reiterates: Buy | $38 → $35 | $14.37 | +143.56% | 2 | Mar 5, 2025 | |
| ARWR Arrowhead Pharmaceuticals | Reiterates: Buy | $51 → $38 | $13.03 | +191.63% | 7 | Feb 14, 2025 | |
| VKTX Viking Therapeutics | Reiterates: Buy | $109 → $96 | $27.55 | +248.46% | 2 | Feb 7, 2025 | |
| NKTR Nektar Therapeutics | Initiates: Buy | $4 | $0.59 | +579.46% | 1 | Jan 8, 2025 | |
| CGTX Cognition Therapeutics | Upgrades: Buy | $1 → $1.5 | $0.30 | +398.17% | 3 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 → $26 | $5.98 | +335.15% | 19 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33 | $12.30 | +168.29% | 1 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $20 | $5.59 | +257.78% | 9 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $34 | $33.64 | +1.07% | 13 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $18 → $5 | $1.43 | +249.65% | 1 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $122 → $92 | $31.70 | +190.27% | 3 | Jun 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $4 | $4.18 | -4.19% | 3 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $140 | $4.04 | +3,365.35% | 1 | Oct 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $90 | $3.37 | +2,570.62% | 5 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $160 | $2.91 | +5,398.28% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $11 → $5 | $1.93 | +159.07% | 3 | Aug 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $58 → $44 | $1.77 | +2,385.88% | 4 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $90 | $1.65 | +5,354.55% | 4 | Jul 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 → $7 | $6.97 | +0.43% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9,750 → $4,500 | $1.17 | +386,166.09% | 3 | Jan 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $500 → $270 | $1.12 | +24,007.14% | 2 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $138 → $77 | $10.98 | +601.28% | 2 | Jan 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,980 → $1,440 | $1.24 | +116,029.03% | 3 | May 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $4 | $1.38 | +189.86% | 2 | Apr 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $47 → $39 | $95.34 | -59.09% | 2 | Mar 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $11 | $1.47 | +648.30% | 1 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $34 | $4.30 | +690.70% | 1 | Mar 13, 2020 |
Madrigal Pharmaceuticals
May 2, 2025
Reiterates: Buy
Price Target: $422 → $460
Current: $299.69
Upside: +53.49%
Harrow
Apr 1, 2025
Maintains: Buy
Price Target: $69 → $65
Current: $24.40
Upside: +166.39%
Vaxart
Mar 27, 2025
Maintains: Buy
Price Target: $2.5 → $2
Current: $0.42
Upside: +376.64%
Trevi Therapeutics
Mar 19, 2025
Reiterates: Buy
Price Target: $11 → $20
Current: $6.60
Upside: +203.03%
Lineage Cell Therapeutics
Mar 14, 2025
Maintains: Buy
Price Target: $4 → $3
Current: $0.44
Upside: +581.82%
Denali Therapeutics
Mar 5, 2025
Reiterates: Buy
Price Target: $38 → $35
Current: $14.37
Upside: +143.56%
Arrowhead Pharmaceuticals
Feb 14, 2025
Reiterates: Buy
Price Target: $51 → $38
Current: $13.03
Upside: +191.63%
Viking Therapeutics
Feb 7, 2025
Reiterates: Buy
Price Target: $109 → $96
Current: $27.55
Upside: +248.46%
Nektar Therapeutics
Jan 8, 2025
Initiates: Buy
Price Target: $4
Current: $0.59
Upside: +579.46%
Cognition Therapeutics
Dec 19, 2024
Upgrades: Buy
Price Target: $1 → $1.5
Current: $0.30
Upside: +398.17%
Oct 10, 2024
Reiterates: Buy
Price Target: $23 → $26
Current: $5.98
Upside: +335.15%
Sep 19, 2024
Initiates: Buy
Price Target: $33
Current: $12.30
Upside: +168.29%
Aug 12, 2024
Reiterates: Buy
Price Target: $20
Current: $5.59
Upside: +257.78%
Aug 7, 2024
Maintains: Buy
Price Target: $29 → $34
Current: $33.64
Upside: +1.07%
Jul 31, 2024
Downgrades: Neutral
Price Target: $18 → $5
Current: $1.43
Upside: +249.65%
Jun 4, 2024
Maintains: Buy
Price Target: $122 → $92
Current: $31.70
Upside: +190.27%
Dec 20, 2023
Maintains: Buy
Price Target: $8 → $4
Current: $4.18
Upside: -4.19%
Oct 13, 2023
Initiates: Buy
Price Target: $140
Current: $4.04
Upside: +3,365.35%
Apr 10, 2023
Maintains: Buy
Price Target: $210 → $90
Current: $3.37
Upside: +2,570.62%
Mar 29, 2023
Reiterates: Buy
Price Target: $160
Current: $2.91
Upside: +5,398.28%
Aug 19, 2022
Downgrades: Neutral
Price Target: $11 → $5
Current: $1.93
Upside: +159.07%
Aug 11, 2022
Maintains: Buy
Price Target: $58 → $44
Current: $1.77
Upside: +2,385.88%
Jul 14, 2022
Maintains: Buy
Price Target: $120 → $90
Current: $1.65
Upside: +5,354.55%
May 24, 2022
Downgrades: Neutral
Price Target: $14 → $7
Current: $6.97
Upside: +0.43%
Jan 24, 2022
Maintains: Buy
Price Target: $9,750 → $4,500
Current: $1.17
Upside: +386,166.09%
Nov 30, 2021
Maintains: Buy
Price Target: $500 → $270
Current: $1.12
Upside: +24,007.14%
Jan 15, 2021
Downgrades: Neutral
Price Target: $138 → $77
Current: $10.98
Upside: +601.28%
May 22, 2020
Downgrades: Neutral
Price Target: $1,980 → $1,440
Current: $1.24
Upside: +116,029.03%
Apr 3, 2020
Maintains: Buy
Price Target: $8 → $4
Current: $1.38
Upside: +189.86%
Mar 18, 2020
Maintains: Buy
Price Target: $47 → $39
Current: $95.34
Upside: -59.09%
Mar 13, 2020
Maintains: Buy
Price Target: $22 → $11
Current: $1.47
Upside: +648.30%
Mar 13, 2020
Maintains: Buy
Price Target: $43 → $34
Current: $4.30
Upside: +690.70%